AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

All participants had undergone prior rounds of endocrine-based therapy and at least one systemic treatment ... but showed a ...

Wall Street analysts have high expectations for datopotomab deruxtecan, which is part of a lucrative alliance between AstraZeneca and Daiichi and is in clinical ... Overall survival was one of the two ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

The tiny sample will be studied for clues about conditions inside the reactors -- a crucial step towards decommissioning the Fukushima Daiichi plant ... triggered one of the world's worst nuclear ...

On Tuesday, Daiichi Sankyo Company, Limited (4568 ... However, there was a report of one ILD-related death at the 8mg/kg dose level. The company's stock rating and price target have been ...

(Bloomberg) -- Shares of AstraZeneca Plc and Daiichi Sankyo Co. tumbled after the pair’s lung cancer drug showed mixed results in a late-stage trial. Astra dropped as much as 5.4% in early London ...

It is available for both Apple and Android devices. In 2022, Etisalat launched the GoChat Messenger, an all-in-one free voice and video calling app. The app is available for Apple, Android and ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's datopotamab deruxtecan (Dato ... who had previously undergone at least one line of therapy. In the overall trial population, OS results numerically ...

Among the many mysteries that One Piece has yet to explain, the Voice of All Things is undoubtedly one of the most fascinating. This is a rare trait that only a chosen few possess, and it allows ...